Is Viatris Stock a Buy Now?
Pharmaceutical businesses spend billions of dollars developing medicines that they then protect with a fortress of intellectual property (IP) safeguards to make sure that competitors can't benefit from their work. But if you're not looking for dividend payments, it's hard to see how it would outperform the market, since it isn't engaged in a high-growth niche, nor is it planning to make significant innovations that would give it an edge over the competition.